Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Feb;103(2):210-216.
doi: 10.1002/cpt.911. Epub 2017 Nov 20.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz  1 , Linda M Henricks  2 , Steven M Offer  3 , Julia Barbarino  4 , Jan H M Schellens  2   5 , Jesse J Swen  6 , Teri E Klein  4 , Howard L McLeod  7 , Kelly E Caudle  8 , Robert B Diasio  3   9 , Matthias Schwab  10   11   12
Affiliations
Practice Guideline

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz et al. Clin Pharmacol Ther. 2018 Feb.

Abstract

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

References

    1. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215–37. - PubMed
    1. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical pharmacology and therapeutics. 2011;89:464–7. - PMC - PubMed
    1. Wei X, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 1998;51:391–400. - PubMed
    1. CPIC. CPIC® Guideline for Fluoropyrimidines and DPYD. < https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/>.
    1. Van Kuilenburg AB, et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer. 1997;33:2258–64. - PubMed

Publication types

MeSH terms